Isodiol Acquires 19.9% of Compass

Isodiol International Inc., a leading bioactive cannabidiol (CBD) innovator, has signed a definitive agreement to acquire 19.9% of Compass Cannabis Clinic.

Compass Cannabis Clinic is a leading Canada-based medical cannabis consultation provider. It focuses on educating and providing consultation to obtain medical cannabis under Canada’s Access to Cannabis for Medical Purposes Regulations. The company is located in British Columbia and Alberta.

With the existing operations in medical business and proposed retail expansion, Compass has successfully established itself as Canada’s largest medical cannabis network. In addition to this, legalization of medical cannabis will further boost the growth of its medical and retail business model.

The agreement will give Isodiol the rights to distribute its exclusive CBD brands through the massive Compass distribution network. In addition to this, Isodiol will reap benefits through Compass’s prime locations, free appointments, and extraordinary patient education and support services. In return, Isodiol will provide Compass with a private label of  THC-free CBD products to cater to its fast-growing patient base.

Besides this, the strategic relationship with Isodiol will also help Compass expand its footprints and medical operations overseas. Compass is utilizing its existing operational tie-ups to enter the Australian market in the third quarter of 2018. Also, the company is actively pursuing more retail licensing opportunities across Canada. It has already established its footprint in the western region of Canada.

As per the agreement, Isodiol will pay $2 million in cash and $2 million in stock to complete the equity acquisition. However, the entire deal is subject to 36-month escrow.

Isodiol is a renowned market leader in pharmaceutical-grade CBD products. The company is a pioneer in the cannabis industry for commercializing 99%+ pure and bioactive cannabidiol. In addition to this, the company utilizes micro-encapsulation and nanotechnology to produce CBD-infused consumer products. The CBD innovator is continuously expanding its portfolio of phytoceutical compounds. It is also expanding its footprints on international soils like Latin America, Asia, and Europe.


Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’

Leave a Reply

Your email address will not be published.